drugset / Trial / NCT07217678
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
Timeline
- Start
- 2026-02-09
- Primary completion
- 2028-01-31
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimatoprost | Other / unclassified | 10 ug | Other |